title: Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty.
abstract: OBJECTIVE
  To report the effect of long-term treatment with the tyrosine kinase inhibitor imatinib started before the onset of puberty on semen parameters, bone mineral density, and hormone values.
  
  
  METHODS
  Case report.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  An 18-year-old man given treatment with imatinib for chronic myeloid leukemia.
  
  
  METHODS
  Clinical, biochemical and dual-energy X-ray absorptiometry evaluations.
  
  
  METHODS
  Semen analysis, serum levels of gonadotropins, inhibin-B, and testosterone, bone mineral density, markers of skeletal homeostasis.
  
  
  RESULTS
  Semen analyses showed severe oligozoospermia after long-term administration of imatinib started before puberty. The inhibin-B/FSH ratio was reduced. A low bone mineral density for chronologic age was observed.
  
  
  CONCLUSIONS
  This case study documents the potential risk of an impairment of semen parameters in patients undergoing a treatment with tyrosine kinase inhibitors before the complete maturation of the testis.
authors.affiliation: Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Mariani
authors.forename: Sabrina
authors.initials: S
authors.lastname: Basciani
authors.forename: Andrea
authors.initials: A
authors.lastname: Fabbri
authors.forename: Luciano
authors.initials: L
authors.lastname: Agati
authors.forename: Salvatore
authors.initials: S
authors.lastname: Ulisse
authors.forename: Carla
authors.initials: C
authors.lastname: Lubrano
authors.forename: Giovanni
authors.initials: G
authors.lastname: Spera
authors.forename: Lucio
authors.initials: L
authors.lastname: Gnessi
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy*; D008297:Male; D009845:Oligospermia / Q000139:chemically induced*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011627:Puberty; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012720:Severity of Illness Index
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate